LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EFIB 2025 Brussels Statement

08/04/2025
Introduction: A mandate for leadership, competitiveness and resilience

The EU is at a critical moment in time, with a need to deliver on political ambitions to build economic strength and resilience now. Europe must anchor and grow its innovation to industrial scale and create a fertile ecosystem for global investment into capacity and supply chains. The 2024 Draghi and Letta reports created a clear direction for EU advancement.

Industrial biotechnology is a critical technology for the EU, building competitive positioning amidst a rapid global shift towards biomanufacturing and establishing flexible production capacity. It strengthens, simplifies and shortens complex global supply chains across sectors. It also reduces reliance on external factors and actors and enables the development of de-fossilised (low carbon), regenerative and circular products in line with Green Deal goals. Most compellingly, it can deliver the scale required for this rapidly, building from Europe’s significant biotechnology foundation within research and industry.

With a cluster of over 25 legislations and initiatives that are directly relevant to biotechnology, the current EU mandate period to 2029 offers the opportunity to deliver an industrial framework for biotechnology from which strong and diverse outcomes can be achieved. Headlines include the EU Biotechnology Act in addition to the Bioeconomy and Life Science Strategies.

This presents the opportunity to amplify European leadership for the transformation of innovation into biomanufacturing, and the EFIB Brussels Statement will champion the key elements required to unlock industrial success by 2029.

Industrial biotechnology as Europe’s critical strategic technology

Industrial biotechnology uses enzymes, microorganisms and living cells to make biobased products from renewable raw materials and includes fermentation at a commercially competitive scale. This is a key enabler of the EU’s transition from a fossil-based economy to a sustainable bioeconomy, across sectors including chemicals, pharmaceuticals, agri-food, fragrances, detergents, paper and pulp, textiles and bioenergy.

Within this mandate, Europe must deliver the coherent legislative framework through which innovation can flourish and mature, and industry can invest to build long term capacity, adaptability and resilience for Europe’s needs.

It must strengthen existing sector outputs and enable new sector pathways to grow, driven by Europe’s innovation excellence, combining next generation products and transforming manufacturing platforms to stay competitive.

EFIB Brussels Statement – a competitive future for the EU

The 2023 EFIB Rotterdam Statement had three main asks 1) Modernisation of regulation and policy 2) Creating a global perspective and 3) Financing enabling technologies.  In 2024, the EU Commission launched a Biotech and Biomanufacturing Communication including a regulatory simplification study and announced the EU Biotech Act.

The 2025 EFIB Brussels Statement builds on this successful recognition of biotech and looks ahead to the decisions that the EU must now take through the policies and initiatives currently in process. A key opportunity exists for societal and industrial transformation within the sustainability and safety ambitions that make Europe a global figurehead.

Ask 1: Regulation and policy. Aligned and ambitious modernisation for innovation leadership

The legislative cluster, led by the Biotech Act, must reflect coherence on the enablement of biotechnology across elements and a stronger framework for implementation at Member State level.

Europe should strive to achieve simplification and acceleration within existing safety standards to strengthen value chains from R&D to end users and enable the competitive flow and maturation of innovation.

Regulatory pathways should support innovation, yielding with it the competitive advantage conferred through global leadership for breakthrough advances and making the EU an attractive destination for global investment.

Ask: Ensure a streamlined, coherent and predictable legislative environment for industrial biotechnology innovation and biomanufacturing that enables the full strength of the Single Market.

Ask 2: Securing a global position in key supply chains. Capacity for resilience and feedstock

Europe should have the goal to ensure supply chain security within a global context through biotechnology capacity and ecosystems that reflect the skills, employment and logistics required for adaptability and rapid response.

Achieving de-fossilised production at scale through biomanufacturing should be a priority outcome from legislative modernisation with attention towards key strategic supply chains for the EU. It is also crucial to have reliable and cost competitive feedstocks for the success of EU's Bioeconomy

Ask: Europe must identify and strengthen key supply chains through enhanced capacity and skills here and leadership in export and partnership.

Ask 3: Financing innovation. Enabling technologies

The EU should enable and incentivise public and private investment (separately and combined) into the translation of biotechnology innovation into manufacturing at scale.

There should be proactive facilitation of viable business pathways for large scale biomanufacturing, including level playing field across sectors, technologies, Member States and global regions, with incentives and lead market pathways to unlock competitiveness.

Financial frameworks must be matured to reflect the unique requirements and potential of industrial biotechnology, including fermentation and the requirement for consistent and accessible feedstock.

Ask: Ensure speed and scale of finance through public and private pathways for the development and deployment of next generation biotechnology innovation towards EU growth and global performance.

EU Biotechnology legislative cluster 2025-2029

EFIB 2025 Brussels Statement


Download
Share
Adrian Lincoln
Adrian Lincoln

Related posts

22/05/2025

Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World


Read more
21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
16/04/2025

EuropaBio position on the EU Life Sciences Strategy


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.